March 21 (Reuters) - Arch Biopartners :
* ARCH BIOPARTNERS GRANTED PRE-IND MEETING WITH FDA FOR CANDIDATE DRUG TO PREVENT ACUTE KIDNEY INJURY
* ARCH BIOPARTNERS INC - PRE-IND MEETING WITH U.S. FDA DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS DCRP WILL TAKE PLACE ON APRIL 18, 2018
* ARCH BIOPARTNERS - SUBMITTED INFORMATION PACKAGE TO FDA DCRP CONTAINING QUESTIONS & DRAFT IND APPLICATION CONTENT
* ARCH BIOPARTNERS - MEETING FDA TO REVIEW, CONFIRM KEY COMPONENTS OF A PLANNED IND APPLICATION FOR METABLOK AS TREATMENT TO PREVENT ACUTE KIDNEY INJURY